Gsk Share Discussion Threads

[netcurtains] 24/6/2022 10:02

Relx up 3%

[pierre oreilly] 24/6/2022 09:57

Yes.

But impossible to know what the chance is or how you'd work it out!

[netcurtains] 24/6/2022 09:46

any chance this will break 1800 today?

[johnrxx99] 24/6/2022 09:29

I bow to your superior knowledge.

[tradermichael] 24/6/2022 09:08

Burroughs Wellcome became Wellcome became Glaxo Wellcome became GlaxoSmithKline became GSK.

Splitting off from Burroughs Wellcome became Wellcome Trust, the most philanthropic of all..

[maywillow] 24/6/2022 07:03

Sanofi SA said Friday that its coronavirus booster vaccine, developed alongside Britain's GSK PLC, has produced successful results against the Omicron variant of the coronavirus in an efficacy study.

The French biopharmaceutical company said its vaccine candidate showed efficacy against the virus in an environment of high Omicron variation. It showed 72% efficacy against the strain in adult, as well as a favorable safety and tolerability profile, the company said.

Along with positive data from two previous trials, the results will be submitted to regulatory authorities for approval, Sanofi said.

The results "indicate the potential of Sanofi-GSK's next-generation Beta-based booster to be a relevant response to public health needs," the company said.



Write to Joshua Kirby at [e-mail]; @joshualeokirby



(END) Dow Jones Newswires

June 24, 2022 02:06 ET (06:06 GMT)

[johnrxx99] 24/6/2022 04:10

Welcome also.

[gibbs1] 23/6/2022 15:26

Michele Maatouk
Sharecast News
23 Jun, 2022 15:21 23 Jun, 2022 15:26


GlaxoSmithKline to invest £1bn in infectious disease R&D


GlaxoSmithKline said on Thursday it will invest £1bn over ten years to accelerate research and development (R&D) into infectious diseases that disproportionately impact lower-income countries.



The research will focus on new and disruptive vaccines and medicines to prevent and treat malaria, tuberculosis, HIV (through ViiV Healthcare), neglected tropical diseases and anti-microbial resistance, which Glaxo said “continue to have a devastating toll on the most vulnerable, accounting for more than 60% of the disease burden in many lower-income countries".

Thomas Breuer, GSK’s chief global health officer, said: "I am delighted to renew our commitment to global health research for the coming decade, consistent with our purpose to unite our science, technology, and talent to get ahead of disease together and our ambition to deliver health impact at scale.

"Through our focus on scientific innovation in Global Health, we have delivered the first malaria vaccine, RTS,S, the first radical cure of vivax malaria, tafenoquine, and a new tuberculosis vaccine candidate."

He noted that the company now has more than 30 potential new vaccines and medicines - including pre-clinical assets - in 13 high-burden infectious diseases to accelerate.

[alphorn] 23/6/2022 13:21

Pfizer - eg. river blindness from memory.

[jonjoneil] 23/6/2022 13:14

Can't imagine Pfizer doing this.

[gateside] 23/6/2022 13:12

I think pharmaceutical companies often feel they have a philanthropic obligation to help mankind.I do agree it should probably be voted upon. And if so I'm sure it would pass easily.

[jonjoneil] 23/6/2022 12:58

TM
I totally agree. It's not their money.
Charitable donations should be kept separate from investments.

[tradermichael] 23/6/2022 11:49

I would have thought that this should be subject to a shareholder vote:


GSK PLC said Thursday that it will invest 1 billion pounds ($1.23 billion) to accelerate research and development over the next 10 years, targeting infectious diseases that disproportionately affect lower-income countries.

The British pharmaceutical company, formerly known as GlaxoSmithKline, said the investment will focus on new and disruptive vaccines and medicines to prevent and treat malaria, tuberculosis, HIV, neglected tropical diseases and anti-microbial resistance. These account for more than 60% of the disease burden in lower-income countries, the company said.

To deliver against its targets, GSK has formed a dedicated, non-commercial global health unit, measuring success by its effects on health alone without the concern of a commercial return on investment. This includes global health research and development hubs, which are advancing more than 30 potential new vaccines and medicines, targeting 13 high-burden infectious diseases.

[tradermichael] 21/6/2022 12:55

Seems to be a 'fashion' trend right now to split large global businesses, but this one is very strange:

Kellogg's has announced it's spinning off its cereal business as it plans to separate into three independent companies. It plans to separate into three independent public companies, sectioning off its iconic brands into distinct snacking, cereal and plant-based businesses.

The US food giant, which owns brands including Corn Flakes and Coco Pops, said the break-up will give each business a better chance to grow.

Steve Cahillane, chief executive of Kellogg, said: "These businesses all have significant standalone potential, and an enhanced focus will enable them to better direct their resources toward their distinct strategic priorities."

[tradermichael] 21/6/2022 12:50

It is, GSK intends to monetise its holding in Haleon in a disciplined manner to further strengthen the Company’s balance sheet.

[jonjoneil] 21/6/2022 12:33

Thanks TM.
I wonder why Glaxo couldn't have divested consumer in the same way?

[tradermichael] 21/6/2022 11:52

Prior to the Demerger, GlaxoSmithKline Consumer Healthcare Holdings (No. 2) Limited (“JVCo”), the current holding company of the Consumer Healthcare business, will pay dividends to GSK and Pfizer.

32 per cent. of HAL total ordinary ordinary share capital will be held by Pfizer. In keeping with Pfizer’s transformation into a more focused, global leader in science-based innovative medicines and vaccines, Pfizer intends to exit its 32 per cent. ownership interest in Haleon in a disciplined manner, with the objective of maximising value for Pfizer shareholders.

[jonjoneil] 21/6/2022 09:07

How are Pfizer handling their part of the split?

[anhar] 21/6/2022 09:00

Consolidations are common, usually accompanying a substantial cash return though in this case it's the demerger. In effect they compel the sale of part of your holding. You end up with fewer shares in the original company but in return some cash, or in this case Haleon shares.

Their purpose is to try and maintain approx the same share price before and after the consol for cosmetic purposes because a big price drop doesn't look too attractive. It's rather craven of the companies and I find them something of a nuisance though I do welcome cash returns and demergers.

Note that consols are not essential in these situations. For instance BHP recently distributed WDS shares with a seriously large sum involved, but did not bend to the consol fashion that most companies would in this situation. Good for them I think.

[tradermichael] 21/6/2022 08:53

Not in ISAs, liable for CGT!

[lippy4] 21/6/2022 08:27

if they are all held in a isa no problems...

[tradermichael] 21/6/2022 08:25

Yes, but its more complex than that.

For example, if they are sold separately at different times ..... what cost new GSK, what cost Haleon?

[jonjoneil] 21/6/2022 08:01

ISAy ISAy ISAy. Don't have that problem.

Surely, if you sold both companies in the same tax year the base cost would be the same as if you sold them now. Any gain would be on the two companies added together.

[spyder] 21/6/2022 07:35

—> TM
I suspect that the calculation will be quite complex, but that the company will advise us once the transaction is completed?

[tradermichael] 21/6/2022 06:17

Question is:

If you held Company A and later sell new Company A and Company B and make a gain, what price do you apply to the Capital Gain calculation as the base cost of the shares for tax purposes?